<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary M Cox, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Perfect, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Cryptococcus neoformans</em> meningoencephalitis is the most frequently encountered manifestation of cryptococcosis. The term "meningoencephalitis" is more appropriate than "meningitis" since histopathologic examination has demonstrated that the brain parenchyma is almost always involved.</p><p>Cryptococcal meningoencephalitis is an important opportunistic infection in immunosuppressed patients. Issues related to patients with human immunodeficiency virus (HIV) are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/85376.html" rel="external">"Clinical management and monitoring during antifungal therapy for cryptococcal meningoencephalitis in persons with HIV"</a>.)</p><p>The pathogenesis, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in patients without HIV will be reviewed here. Other issues related to <em>C. neoformans</em> infection are discussed separately. <em>Cryptococcus gattii</em> infection is also presented separately. (See  <a class="medical medical_review" href="/d/html/2448.html" rel="external">"Microbiology and epidemiology of Cryptococcus neoformans infection"</a> and  <a class="medical medical_review" href="/d/html/2443.html" rel="external">"Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV"</a> and  <a class="medical medical_review" href="/d/html/2421.html" rel="external">"Cryptococcus neoformans infection outside the central nervous system"</a> and  <a class="medical medical_review" href="/d/html/16624.html" rel="external">"Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/85842.html" rel="external">"Cryptococcus gattii infection: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/90020.html" rel="external">"Cryptococcus gattii infection: Treatment"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span><em>C. neoformans</em> causes infection following inhalation through the respiratory tract. The organism disseminates hematogenously and has a propensity to localize to the central nervous system (CNS). The basis for the tropism for the CNS is uncertain, but several hypotheses have been proposed:</p><p class="bulletIndent1"><span class="glyph">●</span>The cerebrospinal fluid (CSF) is a favorable growth medium for the organism as it lacks the factors present in serum that inhibit cryptococcal growth [<a href="#rid1">1</a>]. In the serum, the organism activates the alternative complement pathway, but complement activity in the CSF is very low [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dopamine levels in the CNS may promote cryptococcal virulence by serving as a substrate for melanin production by the organism [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/2448.html" rel="external">"Microbiology and epidemiology of Cryptococcus neoformans infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Production of <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> by the organism may contribute to brain edema and inhibit phagocyte function [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>C. neoformans</em> appears to evade the host innate immune system and invade through the blood-brain barrier [<a href="#rid5">5</a>].</p><p></p><p>The inflammatory response in the brain is generally milder than that seen in bacterial meningoencephalitis. The inflammatory cell infiltrate is predominantly comprised of mononuclear cells with occasional polymorphonuclear leukocytes. In general, involvement of the brain is diffuse, but localized infection (ie, cryptococcoma) can also occur.</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Most patients with cryptococcal meningitis are immunocompromised. The most common forms of immunosuppression, other than HIV, include glucocorticoid therapy, solid organ transplantation, cancer (particularly hematologic malignancy), and other conditions such as sarcoidosis and hepatic failure. Other risk factors include the use of the tyrosine kinase inhibitor, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> [<a href="#rid6">6</a>], and the development of anti-granulocyte-macrophage colony stimulating factor (anti-GM-CSF) antibodies [<a href="#rid7">7</a>]. Although many patients have risk factors for disease, in a multicenter retrospective study of 157 cases of central nervous system (CNS) cryptococcosis in patients without HIV, 30 percent had no apparent underlying condition [<a href="#rid8">8</a>]. </p><p>Additional information on the epidemiology of cryptococcal infection is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2448.html" rel="external">"Microbiology and epidemiology of Cryptococcus neoformans infection"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Clinical presentation of cryptococcal meningoencephalitis in patients without HIV is variable. Some patients have symptoms for up to several months prior to diagnosis, whereas others present with an acute illness of only a few days. Most patients present with signs and symptoms of subacute meningoencephalitis; fever is observed in approximately 50 percent of cases [<a href="#rid8">8-10</a>]. Typically, headache, lethargy, personality changes, and memory loss develop over two to four weeks. Patients may also present with disseminated disease. (See  <a class="medical medical_review" href="/d/html/2421.html" rel="external">"Cryptococcus neoformans infection outside the central nervous system"</a>.)</p><p>Among solid organ transplant recipients, cryptococcal infection occurs in an average of 2.8 percent of patients [<a href="#rid11">11,12</a>]. The median time to disease onset is 21 months after transplantation; 68 percent of cases occur &gt;1 year after transplantation. Central nervous system (CNS) involvement and disseminated infection have been documented in 52 to 61 percent of patients with cryptococcal infection [<a href="#rid11">11,13</a>]. Approximately 25 percent of transplant recipients with <em>C. neoformans</em> disease have fungemia [<a href="#rid11">11,14</a>].</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnosis of cryptococcal meningoencephalitis can be challenging because of the subacute onset of symptoms and nonspecific presentation. The disease should be suspected in any immunocompromised patient with fever, headache, and signs or symptoms referable to the central nervous system (CNS). <em>C. neoformans</em> should also be considered in immunocompetent individuals presenting with subacute to chronic meningitis. A lumbar puncture is necessary to definitively diagnose cryptococcal meningoencephalitis, although this procedure should be delayed in the setting of focal neurologic signs, papilledema, or impaired mentation pending the results of radiographic imaging.</p><p class="headingAnchor" id="H6"><span class="h2">Cerebrospinal fluid</span><span class="headingEndMark"> — </span>Lumbar puncture with measurement of the opening pressure and careful evaluation of the cerebrospinal fluid (CSF) with India ink, polymerase chain reaction (PCR) CSF testing, and/or cryptococcal antigen testing should suggest the diagnosis in most cases. Culture nearly always establishes the diagnosis.</p><p class="bulletIndent1"><span class="glyph">●</span>The opening pressure may be markedly elevated. Almost 70 percent of acquired immunodeficiency syndrome (AIDS) patients with cryptococcal meningoencephalitis have opening pressures &gt;200 mmH<sub>2</sub>0 on the initial lumbar puncture [<a href="#rid9">9</a>]. Increased intracranial pressure is observed less frequently in patients without HIV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cell counts of the CSF are characteristically low in HIV-associated infection (0 to 50 cells/microL), and higher in non-HIV-associated cases (20 to 200 cells/microL). Mononuclear cells predominate in patients with cryptococcal meningoencephalitis (50 to 80 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low glucose levels and elevated protein levels are frequently observed. Inflammatory cell counts have a lymphocytic predominance. Some patients present with normal CSF protein and glucose values [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Examination of the CSF with India ink demonstrates encapsulated yeast forms in approximately 75 percent of patients with HIV and in 50 percent of patients without HIV [<a href="#rid16">16,17</a>]. Gram stain is usually not sufficient since the organisms stain poorly and can be confused with host cells  (<a class="graphic graphic_picture graphicRef58455 graphicRef63752 graphicRef75483" href="/d/graphic/58455.html" rel="external">picture 1A-C</a>).</p><p></p><p>The diagnosis of cryptococcal meningoencephalitis is established by culturing the organism from the CSF. Cultures are positive in about 90 percent of patients without HIV. <em>C. neoformans</em> usually takes three to five days to grow in the laboratory. At least 3 to 5 mL of CSF should be used for culture; the yield may be increased by culturing more than 15 mL of CSF [<a href="#rid16">16,18</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Cryptococcal antigen</span><span class="headingEndMark"> — </span>Cryptococcal antigen testing is a useful tool in the diagnosis of cryptococcal meningoencephalitis. Antigen testing can be collected in the CSF or the serum and can be quantified by evaluating serial dilutions. The height of the antigen titer generally correlates with the burden of organisms. However, serial measurement of antigen titers is not a reliable indicator of response to therapy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>In the CSF</strong> − CSF cryptococcal antigen should be sent in addition to CSF culture when cryptococcal meningoencephalitis is suspected. Antigen test results are generally available soon after the lumbar puncture is performed and can help make the diagnosis before the culture results are complete. The antigen test is very sensitive and specific in the CSF. In a study of five antigen tests (four latex agglutination assays and one enzyme-linked immunoassay), all had sensitivities ranging from 93 to 100 percent and specificities of 93 to 98 percent compared with culture [<a href="#rid19">19</a>]. More recently, a lateral flow assay has been developed for cryptococcal antigen detection, which is inexpensive, easy to perform, and accurate [<a href="#rid20">20</a>]. False-positive CSF cryptococcal antigen results have been reported rarely following exposure of samples to disinfectants or soap or after samples were placed into an anaerobic transport vial [<a href="#rid21">21-23</a>]. (See  <a class="medical medical_review" href="/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV", section on 'Cryptococcal antigen (CrAg)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In the serum</strong> − If a lumbar puncture cannot be performed expediently, serum cryptococcal antigen testing can be helpful to support the diagnosis if positive. However, it cannot be reliably used to rule out cryptococcal meningoencephalitis in patients without HIV. Because patients without HIV tend to have a lower cryptococcal burden, the sensitivity of serum antigen testing is lower than in patients with HIV [<a href="#rid24">24</a>]. False-negative serum cryptococcal antigen tests can also occur with samples that contain a large amount of antigen (the prozone phenomenon) if the laboratory is using a latex agglutination assay and doesn't pretreat the sample with pronase [<a href="#rid19">19</a>]. Among organ transplant recipients, patients with CNS or disseminated cryptococcosis are more likely to have a positive serum cryptococcal antigen result than patients with limited pulmonary disease [<a href="#rid14">14</a>]. False-positive serum cryptococcal antigen tests can occur in the setting of infections due to the fungus<em> Trichosporon asahii</em> (formerly<em> Trichosporon beigelii</em>) or the bacterial genera<em> Stomatococcus </em>or<em> Capnocytophaga </em>[<a href="#rid25">25-27</a>]. (See  <a class="medical medical_review" href="/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV", section on 'Cryptococcal antigen (CrAg)'</a>.)</p><p></p><p class="headingAnchor" id="H345990388"><span class="h2">Cryptococcal PCR</span><span class="headingEndMark"> — </span>A multiplex polymerase chain reaction (PCR) assay has been found to be useful for the diagnosis of cryptococcal meningitis in patients with HIV infection (&gt;90 percent sensitivity and specificity) [<a href="#rid28">28</a>]. However, with the lower burden of CSF yeasts in many patients without HIV, this test may be less sensitive [<a href="#rid29">29,30</a>]. Additional information about the use of this test in patients with HIV is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV", section on 'Cryptococcal PCR'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Extraneural cultures</span><span class="headingEndMark"> — </span>The diagnosis of cryptococcal meningoencephalitis is occasionally made by recovering <em>C. neoformans</em> from an extraneural site before CNS disease is suspected. This is especially true in patients with HIV infection who have a high likelihood of extraneural disease involving the respiratory tract, urinary tract, or bloodstream at the same time as CNS infection. As an example, blood cultures have been positive for cryptococci in approximately two-thirds of HIV-associated cases of meningoencephalitis [<a href="#rid18">18</a>].</p><p>Therefore, lumbar puncture should be considered for patients with positive serum cryptococcal antigen or extraneural culture to rule out CNS involvement. Immunocompetent individuals with only pulmonary involvement who have no CNS signs or symptoms may not require a lumbar puncture prior to treatment. (See  <a class="medical medical_review" href="/d/html/2421.html" rel="external">"Cryptococcus neoformans infection outside the central nervous system"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Radiography</span><span class="headingEndMark"> — </span>Radiographic imaging of the brain with computed tomography (CT) or magnetic resonance imaging (MRI) prior to lumbar puncture is important in the setting of focal neurologic signs, papilledema, or impaired mentation. MRI is more effective than CT for identifying CNS cryptococcal lesions [<a href="#rid31">31</a>].</p><p>Radiographic images frequently show no abnormality or cerebral atrophy without obstruction or other pathology [<a href="#rid32">32</a>]. Less commonly, hydrocephalus may be seen. Mass lesions are seen in about 10 percent of patients with CNS cryptococcal infections [<a href="#rid9">9</a>]. Acute and subacute cerebral infarcts have also been described [<a href="#rid10">10,33</a>].</p><p>Some brain lesions persist radiographically for long periods even in those who have had a good clinical response to therapy [<a href="#rid32">32</a>]. Lesions that develop surrounding edema during effective therapy are typically due to an immunologic response associated with control of infection, the so-called immune reconstitution inflammatory syndrome [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome", section on 'IRIS associated with preexisting cryptococcal infection'</a>.)</p><p class="headingAnchor" id="H2214067729"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113059.html" rel="external">"Society guideline links: Cryptococcosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions and pathogenesis </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Cryptococcus neoformans</em> meningoencephalitis is the most frequently encountered manifestation of cryptococcosis. The term "meningoencephalitis" is more appropriate than "meningitis" since histopathological examination has demonstrated that the brain parenchyma is almost always involved. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>C. neoformans</em> causes infection following inhalation through the respiratory tract. The organism disseminates hematogenously and has a propensity to localize to the central nervous system. The inflammatory response in the brain is generally milder than that seen in bacterial meningoencephalitis. The inflammatory cell infiltrate is predominantly comprised of mononuclear cells with occasional polymorphonuclear leukocytes. In general, involvement of the brain is diffuse, but localized infection (ie, cryptococcoma) can also occur. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>–<strong> </strong>Most patients with cryptococcal meningitis are immunocompromised. The most common forms of immunosuppression other than HIV include glucocorticoid therapy, solid organ transplantation, cancer (particularly hematologic malignancy), and other conditions such as sarcoidosis and hepatic failure. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>–<strong> </strong>Clinical presentation is variable. Some patients have symptoms for up to several months prior to diagnosis, whereas others present with an acute illness of only a few days. Fever is observed in approximately 50 percent of cases. Typically, headache, lethargy, personality changes, and memory loss develop over two to four weeks. Patients may also present with disseminated disease (eg, &gt;1 noncontiguous site). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cerebrospinal fluid (CSF) testing </strong>–<strong> </strong>A lumbar puncture is necessary for diagnosis of cryptococcal meningoencephalitis. The opening pressure should be measured, along with India ink evaluation, cryptococcal antigen testing, fungal culture, and routine spinal fluid studies. The diagnosis is established definitively by culturing the organism from the spinal fluid. (See <a class="local">'Cerebrospinal fluid'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serum cryptococcal antigen </strong>–<strong> </strong>Serum cryptococcal antigen testing is useful for evaluation of patients without HIV infection, although a negative result cannot be used to rule out cryptococcal meningoencephalitis. The height of the antigen titer generally correlates with the burden of organisms, although serial measurement of antigen titers is not a reliable indicator of response to therapy. (See <a class="local">'Cryptococcal antigen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Radiography </strong>–<strong> </strong>Radiographic imaging of the brain with CT or MRI prior to lumbar puncture is important in the setting of focal neurologic signs, papilledema, or impaired mentation. Radiographic images frequently show no abnormality or cerebral atrophy without obstruction or other pathology. Less commonly, hydrocephalus may be seen. Mass lesions are seen in about 10 percent of patients with central nervous system cryptococcal infections. (See <a class="local">'Radiography'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Igel HJ, Bolande RP. Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans. J Infect Dis 1966; 116:75.</a></li><li><a class="nounderline abstract_t">Diamond RD, May JE, Kane MA, et al. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol 1974; 112:2260.</a></li><li><a class="nounderline abstract_t">Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 1986; 51:218.</a></li><li><a class="nounderline abstract_t">Wong B, Perfect JR, Beggs S, Wright KA. Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immun 1990; 58:1664.</a></li><li><a class="nounderline abstract_t">Yang CL, Wang J, Zou LL. Innate immune evasion strategies against Cryptococcal meningitis caused by Cryptococcus neoformans. Exp Ther Med 2017; 14:5243.</a></li><li><a class="nounderline abstract_t">Messina JA, Maziarz EK, Spec A, et al. Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. Open Forum Infect Dis 2017; 4:ofw261.</a></li><li><a class="nounderline abstract_t">Rosen LB, Freeman AF, Yang LM, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol 2013; 190:3959.</a></li><li><a class="nounderline abstract_t">Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690.</a></li><li class="breakAll">Cox GM, Perfect JR. Cryptococcus neoformans var neoformans and gattii and Trichosporon species. In: Topley and Wilson's Microbiology and Microbial Infections, 9th ed, Whiteman W, Topley C, Wilson GS, et al (Eds), Arnold Press, London 1997.</li><li><a class="nounderline abstract_t">Qu J, Zhou T, Zhong C, et al. Comparison of clinical features and prognostic factors in HIV-negative adults with cryptococcal meningitis and tuberculous meningitis: a retrospective study. BMC Infect Dis 2017; 17:51.</a></li><li><a class="nounderline abstract_t">Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7:375.</a></li><li><a class="nounderline abstract_t">Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002; 2:575.</a></li><li><a class="nounderline abstract_t">Shaariah W, Morad Z, Suleiman AB. Cryptococcosis in renal transplant recipients. Transplant Proc 1992; 24:1898.</a></li><li><a class="nounderline abstract_t">Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756.</a></li><li><a class="nounderline abstract_t">Shaunak S, Schell WA, Perfect JR. Cryptococcal meningitis with normal cerebrospinal fluid. J Infect Dis 1989; 160:912.</a></li><li><a class="nounderline abstract_t">Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987; 317:334.</a></li><li><a class="nounderline abstract_t">Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974; 80:176.</a></li><li><a class="nounderline abstract_t">Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326:83.</a></li><li><a class="nounderline abstract_t">Tanner DC, Weinstein MP, Fedorciw B, et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994; 32:1680.</a></li><li><a class="nounderline abstract_t">Hansen J, Slechta ES, Gates-Hollingsworth MA, et al. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol 2013; 20:52.</a></li><li><a class="nounderline abstract_t">Blevins LB, Fenn J, Segal H, et al. False-positive cryptococcal antigen latex agglutination caused by disinfectants and soaps. J Clin Microbiol 1995; 33:1674.</a></li><li><a class="nounderline abstract_t">Boom WH, Piper DJ, Ruoff KL, Ferraro MJ. New cause for false-positive results with the cryptococcal antigen test by latex agglutination. J Clin Microbiol 1985; 22:856.</a></li><li><a class="nounderline abstract_t">Wilson DA, Sholtis M, Parshall S, et al. False-positive cryptococcal antigen test associated with use of BBL Port-a-Cul transport vials. J Clin Microbiol 2011; 49:702.</a></li><li><a class="nounderline abstract_t">Hevey MA, George IA, Rauseo AM, et al. Performance of the Lateral Flow Assay and the Latex Agglutination Serum Cryptococcal Antigen Test in Cryptococcal Disease in Patients with and without HIV. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Chanock SJ, Toltzis P, Wilson C. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 1993; 342:1119.</a></li><li><a class="nounderline abstract_t">McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985; 21:681.</a></li><li><a class="nounderline abstract_t">Westerink MA, Amsterdam D, Petell RJ, et al. Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result. Am J Med 1987; 83:155.</a></li><li><a class="nounderline abstract_t">Rhein J, Bahr NC, Hemmert AC, et al. Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in Uganda. Diagn Microbiol Infect Dis 2016; 84:268.</a></li><li><a class="nounderline abstract_t">Pilmis B, Bougnoux ME, Guery R, et al. Failure of multiplex meningitis/encephalitis (ME) NAT during cryptococcal meningitis in solid organ recipients. Transpl Infect Dis 2020; 22:e13263.</a></li><li><a class="nounderline abstract_t">O'Halloran JA, Franklin A, Lainhart W, et al. Pitfalls Associated With the Use of Molecular Diagnostic Panels in the Diagnosis of Cryptococcal Meningitis. Open Forum Infect Dis 2017; 4:ofx242.</a></li><li><a class="nounderline abstract_t">Charlier C, Dromer F, Lévêque C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One 2008; 3:e1950.</a></li><li><a class="nounderline abstract_t">Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clin Infect Dis 2000; 31:1303.</a></li><li><a class="nounderline abstract_t">Einsiedel L, Gordon DL, Dyer JR. Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman. Clin Infect Dis 2004; 39:e78.</a></li></ol></div><div id="topicVersionRevision">Topic 2447 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5908853" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4596700" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3079732" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2111284" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29285049" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Innate immune evasion strategies against Cryptococcal meningitis caused by Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480254" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23509356" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477526" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477526" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28068915" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of clinical features and prognostic factors in HIV-negative adults with cryptococcal meningitis and tuberculous meningitis: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384512" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12201357" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cryptococcosis in organ transplant recipients: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1412904" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cryptococcosis in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17262720" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2809269" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cryptococcal meningitis with normal cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3299095" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4811791" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prognostic factors in cryptococcal meningitis. A study in 111 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727236" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7929757" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of commercial kits for detection of cryptococcal antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23114703" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7650214" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : False-positive cryptococcal antigen latex agglutination caused by disinfectants and soaps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4056010" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : New cause for false-positive results with the cryptococcal antigen test by latex agglutination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21159939" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : False-positive cryptococcal antigen test associated with use of BBL Port-a-Cul transport vials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32848037" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Performance of the Lateral Flow Assay and the Latex Agglutination Serum Cryptococcal Antigen Test in Cryptococcal Disease in Patients with and without HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105345" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3889042" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605167" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26711635" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32056348" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Failure of multiplex meningitis/encephalitis (ME) NAT during cryptococcal meningitis in solid organ recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29255738" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pitfalls Associated With the Use of Molecular Diagnostic Panels in the Diagnosis of Cryptococcal Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18414656" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073772" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Persistence of cryptococcomas on neuroimaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486830" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
